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Abstract
Significance: In the immune system, nitric oxide (NO) has been mainly associated with antibacterial defenses
exerted through oxidative, nitrosative, and nitrative stress and signal transduction through cyclic GMP-de-
pendent mechanisms. However, S-nitrosylation is emerging as a post-translational modification (PTM) involved
in NO-mediated cell signaling. Recent Advances: Precise roles for S-nitrosylation in signaling pathways have
been described both for innate and adaptive immunity. Denitrosylation may protect macrophages from their
own S-nitrosylation, while maintaining nitrosative stress compartmentalized in the phagosomes. Nitrosothiols
have also been shown to be beneficial in experimental models of autoimmune diseases, mainly through their role
in modulating T-cell differentiation and function. Critical Issues: Relationship between S-nitrosylation, other
thiol redox PTMs, and other NO-signaling pathways has not been always taken into account, particularly in the
context of immune responses. Methods for assaying S-nitrosylation in individual proteins and proteomic ap-
proaches to study the S-nitrosoproteome are constantly being improved, which helps to move this field forward.
Future Directions: Integrated studies of signaling pathways in the immune system should consider whether S-
nitrosylation/denitrosylation processes are among the PTMs influencing the activity of key signaling and
adaptor proteins. Studies in pathophysiological scenarios will also be of interest to put these mechanisms into
broader contexts. Interventions modulating nitrosothiol levels in autoimmune disease could be investigated with
a view to developing new therapies. Antioxid. Redox Signal. 18, 288–308.
Introduction
Since the recognition of nitric oxide (NO) as a secondmessenger in vertebrate cardiovascular and nervous
systems, a classical signaling pathway has been established in
which NO produced by nitric oxide synthase (NOS) stimulates
soluble guanylate cyclase activation, cyclic GMP (cGMP) pro-
duction, and cGMP-activated protein kinases (cGKs or PKGs).
In addition, a less-classical pathway involves the inhibition of
mitochondrial cytochrome c oxidase (complex IV of the elec-
tron transport chain), which has a profound influence on cell
metabolism and homeostasis. Apart from these modes of ac-
tion, several nonclassical mechanisms have been described,
which includeNOproduction fromother sources such as nitrite
anion (NO2
- ) and the covalent post-translational modification
(PTM) of proteins provoked by the so-called reactive nitrogen
species (RNS), a series of chemical species derived from reac-
tions ofNOwith other smallmolecules [reviewed in Ref. (106)].
Among the PTMs induced by RNS, S-nitrosylation [also
called S-nitrosation: see (42, 75, 108) for a discussion of the
terminology] has emerged as an important signaling pathway
related to NO production, with some particularities in terms
of specificity that have been discussed elsewhere (30, 64, 90,
106, 108). It consists in the formation of a nitrosothiol (RSNO,
also called thionitrite) at a protein cysteine thiol (RSH), which
can potentially be achieved through several possible chemical
mechanisms (41, 56, 64). Different structural motifs may
confer specificity to particular cysteine residues in protein
chains (32, 102), suggesting that these distinct pathways
may coexist in any given biochemical environment. As NO
itself is rarely a direct S-nitrosylating agent (unless it reacts
with a thyil radical in the protein cysteine), most of these
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mechanisms proceed through formation of RNS. Other im-
portant parameters driving the specificity of S-nitrosylation
signaling are subcellular compartmentalization and the
proximity to or interaction with NOS, as well as the presence
of denitrosylases and the recently described transnitrosylase
activities (12, 30, 88, 106, 108, 124, 166, 190).
S-nitrosylation is one of several oxidative PTMs produced at
cysteine thiols, such as formation of sulfenic, sulfinic, or sulfonic
acid, of protein intra- or intermolecular disulfide bridges, or of
mixed disulfides with low molecular mass thiols (S-thiolation,
termed S-glutathionylation when formed with glutathione
[GSH]). The relationships among them are complex, including
shared and differential roles in cell signaling and nitroxidative
stress (75, 109). In particular, S-nitrosylation has been shown to
induce disulfide bridges, and especially S-glutathionylation
(5, 109, 183). Indeed, this should be taken into account when
studying the effect of NO donors and nitrosothiols, as they can
produce different types of modifications (106, 109). For exam-
ple, S-nitrosoglutathione (GSNO) is not only a nitrosylating
agent but also a glutathionylating agent (106, 147, 183).
We review here several recently uncovered aspects of the
role of S-nitrosylation in themammalian immune system. One
of them is the influence of S-nitrosylation in toll-like receptor
(TLR) activation and signaling, through the modification of
several proteins and pathways that are mainly involved in
innate immunity, a good example of which is surfactant
protein D (SP-D) modification in the alveolar system. Un-
derstanding the mechanisms that protect macrophages
against their own unbalanced S-nitrosylation when they
are activated through pathways that induce high NO and
RNS production also reflects the implication of nitrosothiol
in innate immunity. NF-kB activation is modulated by S-
nitrosylation at many points of its pathway, which is common
to innate and adaptive immunity. As such, we discuss this in a
middle chapter, together with other proteins and pathways
that are S-nitrosylated and that fulfill diverse roles in the
immune system. In adaptive immunity, most studies dealing
with the role of S-nitrosylation have been conducted on T
cells. S-nitrosylation has been described to take part in specific
signaling pathways during T-cell activation, while it inhibits
T-cell development in the thymus. Finally, we review studies
that have described a role for S-nitrosylation and NO pro-
duction in the differentiation and function of the T-helper cell
subsets involved in chronic inflammatory diseases of auto-
immune origin, for which treatments with nitrosothiols have
been shown to be beneficial in many cases.
In recent years, S-nitrosylation has been shown to play an
important role in the plant immune response, sharing given
mechanisms with animals [for recent references, see Refs. (100,
196)], even though the existence of NOS has yet to be confirmed
in plants (47).While it would certainly be interesting to compare
this response in both kingdoms, this is beyond the scope of this
review. So is the effect of S-nitrosylation on themicrobes that are
attacked by the immune system, for example, those engulfed by
phagocytic cells, which is covered in another review in this
Forum (91a), and in another recent review covering several
chemical mechanisms that depend on ROS and RNS (186).
Nitrosothiols in Innate Immunity
An early defense against infectious agents requires the
participation of innate immune responses, a set of cellular and
biochemical mechanisms representing the organism’s first
line of defense to pathogens. Physical and chemical barriers
(e.g., the respiratory epithelial mucosa and compounds with
antimicrobial activity), cytokines, and phagocytic cells (e.g.,
neutrophils andmacrophages) are themain effectors of innate
immunity. Among the mechanisms by which phagocytes
exert their functions, recent attention has been given to TLRs,
a family of transmembrane proteins that recognize microbe-
derived molecules, many of which are bacterial wall constit-
uents. TLRs increase phagocytosis and cytokine production
mainly through the NF-kB signaling pathway. Ligand bind-
ing to the TLR induces the association of the adaptor MyD88
to its cytoplasmic domain, the recruitment of interleukin-1
receptor (IL-1R)-associated kinase (IRAK) and TRAF-6, and
the ensuing activation of IjB-kinase (IKK), which in turn ac-
tivates NF-jB by inhibiting IjB. This enhances the production
of the proinflammatory cytokines tumor necrosis factor
(TNF)-a, IL-1b, and IL-12 and the expression of adhesion
molecules in activated endothelial cells, which favors the re-
cruitment of leukocytes to inflammatory foci.
Role of SP-D S-nitrosylation in TLR activation
Pulmonary surfactant was initially described as a complex
of lipids and proteins that reduces the surface tension at the
air–liquid interface in the alveoli, thus avoiding atelectasis or
collapsed lung. However, recent studies indicate that a sur-
factant also plays an active role in the innate immune response
(89, 157, 188). Four surfactant proteins have been described
that belong to the family of collagen-like lectins or collectins:
surfactant protein A (SP-A), B (SP-B), C (SP-C), and D (SP-D).
The N-terminal domain of the SP-D monomer contains
two key Cys residues (Cys15 and Cys20), a collagen-like do-
main, a neck region formed by a short a-helix, and a C-type
carbohydrate-recognition domain (CRD) through which it
interacts with anionic phospholipids and complex carbohy-
drates present in pathogens in a Ca2 + -dependent manner (27,
136, 157). It is worth noting that the SP-D monomer does not
seem to be biologically active, but rather the monomers in-
teract through their collagen-like domains to form trimers,
which can oligomerize into a dodecamer through their N-
terminal domains, forming a cruciform structure (27, 136).
This new structure is also able to participate in higher orders
of multimerization (27).
SP-A and SP-D have a pathogen-dependent proin-
flammatory function (49), yet conversely, in a noninflamma-
tory scenario, these collectins can bind to the signal inhibitory
regulatory protein a (SIRP-a) via their CRD, leading to the ac-
tivation of SHP-1 and inhibition of p38 mitogen-activated pro-
tein kinase (MAPK), and thereby suppressing the synthesis of
proinflammatory mediators. However, SP-A and SP-D interact
with pathogens or apoptotic cells through the CRD, allowing
the collagen-like domain at the N-terminus to be presented to
calreticulin/CD91, and therefore triggering a proinflammatory
response through p38 activation. Thus, SP-A and SP-D can act
as both anti-inflammatory and proinflammatory molecules
depending on the environmentwithin the lung (49). SP-D hides
itsN-terminalwithin the dodecamer structure, so its quaternary
structure might be crucial for its immunomodulatory function.
Indeed, oligomerization of SP-D (where disulfide bridges form
between Cys15 and Cys20) has been demonstrated to be critical
for their dual inflammatory role (17, 63, 194).
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Recently, S-nitrosylation of Cys15 and Cys20 has been
shown to play a pivotal role in oligomerization (7, 57), re-
viewed in Ref. (6). This modification disassembles the dode-
camer into trimers, producing macrophage chemotaxis and
triggering a proinflammatory response by activating calreti-
culin/CD91-dependent p38 (57). Under certain conditions,
such as in the presence of pathogen or under nitrosative stress,
S-nitrosylation of SP-D coulddrive the switch between anti- and
proinflammatory activity. As mentioned above, dodecameric
SP-D would act as an anti-inflammatory molecule in basal
conditions. Alternatively, S-nitrosylation of SP-D disassembles
the oligomer into trimers, with the N-terminal domain exposed
and ready to interact with calreticulin/CD91, promoting the
proinflammatory cascade (6, 57) (Fig. 1).
In models of acute lung injury, such as an 8-day exposure to
bleomycin, SP-D S-nitrosylation is reduced by 80% in inducible
nitric oxide synthase (iNOS) knockout mice, suggesting that
this modification is mostly produced by iNOS activity (57).
Thus, since iNOS is expressed in inflammatory scenarios, S-
nitrosylation of SP-Dwould produce positive proinflammatory
feedback (57).
Some questions still require further study. The oligo-
meric form of SP-D can bind to TLR4 (132) and inhibit the
TLR4-dependent proinflammatory response (194). Thus, it
would be of interest to determine whether S-nitrosylation
of SP-D might allow TLR4 receptors to dimerize, activating
and promoting p38-dependent synthesis of proinflam-
matory mediators. Likewise, it remains unknown whether
S-nitrosylation of Cys15/Cys20 in SP-D is necessary for
its interaction with calreticulin/CD91. Finally, it would
be very interesting to assess if other oxidative modifica-
tions of these Cys residues might have a similar functional
relevance.
Macrophage activation and self-protection
by denitrosylases
Macrophage activation by proinflammatory cytokines
(such as interferon-c [IFN-c], produced by other immune cells)
or lipopolysaccharide (LPS) (from the bacterial walls) upre-
gulates iNOS transcription, which produces a burst of NO.
This NO acts as a part of the antimicrobial armory of these
cells, and among other effects (186), it may inactivate through
S-nitrosylation essential proteins of phagocytosed cells (146).
A murine cell line, RAW 264.7, has frequently been used as
a model of macrophage induction to study the role of S-
nitrosylation. Early studies showed that when these cells were
activated by LPS and IFN-c, the amount of S-nitrosothiols in
cell extracts clearly increases, mainly in the protein fraction
(36), which was subsequently confirmed in the same cells (54,
199) and in the J774 macrophage cell line (37). In RAW 264.7
cells, when the intracellular levels of nitrosothiols have been
measured after either the treatment of cells with exogenous
transnitrosylating agents or the endogenous induction of
iNOS, it seems clear that endogenous iNOS induction pro-
duces relatively lower amounts of nitrosothiols, even though
considerable amounts of iNOS-derived NO are produced
(nitrosothiols are estimated at about 0.02% of the nitrite gen-
erated) (199, 200). It is worth noting that in J774 cells, bacterial
infection was recently reported to reduce the nitrosothiol
content of activated macrophages, a process dependent on
genes thought to detoxify NO in such bacteria, namely norB
FIG. 1. S-nitrosylation modulates the quaternary structure and function of surfactant protein D (SP-D). The SP-D
dodecamer binds to signal inhibitory regulatory protein a (SIRP-a) and inhibits p38 mitogen-activated protein kinase (MAPK)
activation via SHP-1, and it also binds toll-like receptor 4 (TLR4), thereby avoiding its dimerization and subsequent acti-
vation. Upon S-nitrosylation, SP-D dodecamers disassemble into trimers, which bind to CD-91/calreticulin, a process that
activates p38 MAPK and triggers a proinflammatory response. Dodecamer disassembly might allow TLR4 dimerization and
downstream activation of NF-jB (To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars).
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(Neisseria meningitidis, meningococcus) and flavohemoglobin,
Hmp (Salmonella enterica and Escherichia coli) (92).
Despite producing large amounts of NO, activated macro-
phagesmay protect themselves against their ownproduction of
such toxic levels of NO and related RNS. It is now clear that
denitrosylases may participate in this protection by acting on
nitrosothiols in proteins and low-molecular-mass thiols, such as
GSH. Two main denitrosylases have been described, which are
related to redox pathways: GSH coupled to GSNO reductase
(GSNOR) (76, 96); and thioredoxin (Trx), coupled to Trx re-
ductase and NADPH (168) [reviewed in Ref. (12); Fig. 2].
GSNOR (also known as GSH-dependent formaldehyde
dehydrogenase) breaks GSNO, and it has been shown to re-
duce protein S-nitrosylation levels, at least in a subset of
proteins whose S-nitrosylation would be in equilibrium with
GSH modification (96). Mice with a targeted deletion of
GSNOR suffer increased S-nitrosylation and mortality after
endotoxic shock induced by LPS, revealing a role in the reg-
ulation of innate immunity (98). In a recent report, a GSNOR
inhibitor profoundly affected the expression of a number of
proteins in activated macrophages (45). By using quantitative
general proteomics (i.e., directed at the general proteome and
not identifying S-nitrosylated proteins), it has been shown
that several inflammatory mediators are downregulated
when GSNOR is inhibited, including iNOS, cyclooxygenase-2
(COX-2), and osteopontin, whereas targets of the Nrf2 tran-
scription factor were upregulated, like heme oxygenase-1 and
glutamate–cysteine ligase modulatory subunit. These results
suggest that a feedback cycle might finely tune the presence
and activity of iNOS, in which Nrf2 may also be implicated
(45). Another protein susceptible of regulation by deni-
trosylation is histone deacetylase 2 (HDAC2). HDAC2 is in-
activated through S-nitrosylation in alveolar macrophages
from chronic obstructive pulmonary disease, which confers
cell resistance to corticosteroid treatment. In this setting, GSH
treatment and induction of Nrf2 restoredHDAC2 activity and
corticosteroid sensitivity, although this GSH- and Nrf2-
dependentmechanismof denitrosylationwas not identified (99).
The role of Trx in denitrosylating particular proteins has
been studied in detail for some proteins such as caspase-3 (11,
13) aswell as using proteomic approaches (see below). It is not
clear if there is an increase in denitrosylation activity during
macrophage activation, or if the basal denitrosylation activity is
sufficient to cope with the increased RNS produced by iNOS
induction. Negative feedback regulators of NOS-dependent
S-nitrosylation have been postulated; for example, the Trx-
interacting protein (Txnip) that inhibits Trx denitrosylation is in
turn inhibited by increased NO levels. Thus, Trx denitrosyla-
tion activity is increased when NO is produced (43). In addi-
tion, Trx itself is a target of S-nitrosylation at several residues,
whose specificity is different in the reduced and oxidized forms
(10), and it can act also as a transnitrosylase (118, 189, 190)
[reviewed inRef. (159)]. Therefore,more detailed studies on the
different roles of Trx in the regulation of S-nitrosylation in
macrophages will be necessary to address this issue.
Further protection could arise through the precise subcel-
lular localization of iNOS in the activated macrophages. Early
reports showed that in primary macrophages, iNOS localizes
in vesicles that could translocate to phagosomes (178). Each of
the three NOS isoforms bears different structural features at
the N- and C-termini that influence their subcellular location.
Cysteine palmitoylation at the N-terminus of iNOS has been
shown to be needed for vesicle association and correct traf-
ficking of the protein through the Golgi apparatus to apical
positions in polarized cells, which is needed for the vectorial
synthesis and release of NO (125, 126). However, to our
knowledge, this has not been studied in macrophages. The
four C-terminal amino acids in iNOS, which become inserted
FIG. 2. Macrophages protect
themselves from inducible
nitric oxide synthase (iNOS)-
induced S-nitrosylation. Pro-
inflammatory stimuli, such as
interferon-c (IFN-c) and lipo-
polysaccharide (LPS), trigger
iNOS expression. This iNOS
associates with vesicles
through the Golgi, and it
may be recruited to phago-
somes where it produces
large amounts of NO that can
S-nitrosylate protein targets
in a phagocyted cell, such as
a bacterium. Thioredoxin
(Trx) and glutathione (GSH)/
S-nitrosoglutathione reduc-
tase (GSNOR) may denitro-
sylate macrophage proteins
that become modified (To see
this illustration in color, the
reader is referred to the web
version of this article at
www.liebertpub.com/ars).
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within PDZ domains, are also needed for its apical localiza-
tion in polarized cells (51, 127). Likewise, in macrophages, the
iNOS C-terminus interacts with the PDZ domains of the cy-
toskeleton scaffolding protein EBP50, which directs iNOS to
the phagosomes (29). Interestingly, the EBP50 gene is induced
in parallel to iNOS, and its recruitment is impaired in Myco-
bacterium tuberculosis-infected phagosomes, which explains
the previously observed exclusion of iNOS from these pha-
gosomes (29, 116).
Macrophage activation, particularly in the murine cell line
RAW 264.7, has been frequently used as a model for the study
of the S-nitrosoproteome, illustrating the sensitivity of the
proteomic methods employed to identify S-nitrosylated pro-
teins. By 2001, more than 100 S-nitrosylated proteins had
been described [see Table S1 in Ref. (167)], all studied on an
individual basis. The original biotin-switch technique (BST)
described by Jaffrey et al. (74) opened the way to study the
S-nitrosoproteome, by describing a method that allowed de-
rivatized S-nitrosylated proteins to be purified, and employ-
ing emergent proteomic techniques to identify the purified
subproteome. However, one study concluded that such
methodology only detected S-nitrosylated proteins when
RAW 264.7 cells were treated with at least 100lM extracel-
lular S-nitroso-l-cysteine, which gave an intracellular S-
nitrosothiol concentration of around 500 nmol/mg protein
(201), well above that produced by endogenous iNOS acti-
vation by proinflammatory cytokines (around 100 pmol/mg
protein) (36, 54, 199). We obtained similar results, as we were
able to detect and identify S-nitrosylated proteins in endo-
thelial cells treatedwith extracellular S-nitroso-l-cysteine (107,
111), but we did not detect S-nitrosylation differences in RAW
264.7 cells after cytokine-dependent induction and activation
of iNOS [results published in Ref. (174), Fig. 3]. However,
another study reported an increase in the S-nitrosylated pro-
tein signal using the BST, identifying up to 15 proteins modi-
fied after cytokine treatment of RAW 264.7 cells (48).
The use of fluorescent derivatization instead of biotin la-
beling, coupled to two-dimensional electrophoresis (2-DE),
has increased the sensitivity of proteomic techniques to study
the S-nitrosoproteome. Although the depth of the proteome
has not been increased (i.e., the number of identified proteins
is not much higher), this approach implies that the starting
material may be 20-fold less (174). However, when applied to
RAW 264.7 cells activated with LPS/IFN-c, we were only able
to detect differentially S-nitrosylated proteins when we in-
cluded auranofin, an inhibitor of the Trx pathway, thereby
identifying putative targets denitrosylated by this path-
way (174). A two-fluorophore scheme for derivatizing S-
nitrosothiols has also been used to detect an overall increase
in S-nitrosylation in cytokine-stimulated RAW 264.7 cells,
mixing samples from nonactivated and activated cells in the
same 2-DE (152). Compared to a one-fluorophore one-sample-
per-gel scheme (174), this approach has two problems: first,
each fluorophore signal has a different normalization pa-
rameter; and second, the amount of total protein in each spot
from each sample is not analyzed, and thus the variations in
the S-nitrosylation signal for a spot may simply be due to a
change in protein abundance [reviewed in Ref. (73)].
Development ofmore sensitive proteomicmethodswill help
to study the S-nitrosoproteome associated with macrophage
activation and the role of the protection mechanisms. These
advances may come from both general improvements in pro-
teomic techniques, such as the use of more powerful mass
spectrometers, as well as through the development of im-
proved protocols and techniques for the specific detection of
this modification. Recent advances in the application of quan-
titative second-generation proteomics (based on large-scale
identification of peptides by tandem mass spectrometry),
coupled to improved derivatization and purification of S-ni-
trosylated peptides, could produce advances in the field, even
in the detection of S-nitrosylated proteins under basal condi-
tions (32, 44). In the RAW 264.7 cell model of cytokine
FIG. 3. The biotin-switch technique (BST) is not sensitive
enough to detect endogenous S-nitrosylation produced by
iNOS activation in macrophages. (A) Murine macrophage
cell line RAW 264.7 was treated with LPS and IFN-c, and
with auranofin, producing iNOS that was detected in west-
ern blots and NO measured as extracellular nitrite with the
Griess reagent. (B) Cell extracts were subjected to the BST,
blotted, and detected with avidin. Although there is a clear
increase in iNOS-derived NO production after LPS + IFN-c
activation, differences in S-nitrosylation are only observed
when the Trx pathway is inhibited with auranofin. Reprinted
by permission from Tello et al. (174).
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activation, two methods have recently been applied that use
stable isotope labeling in culture or label-free spectral counting,
coupled to the purification of derivatized S-nitrosylated pep-
tides. Through thesemethods, 17 or 27 proteinswere described
that were S-nitrosylated after cytokine activation (198, 203).
More detailed studies on the S-nitrosoproteome of macro-
phages during activation, combined with studies into the role
of S-nitrosylation in particular proteins, could shed light on
the mechanisms that could be operating in self-protection
(such as denitrosylation and subcellular localization), as well
as on the interaction with phagocytosed cells.
S-Nitrosylation in Innate and Adaptive Immunity
NF-kB pathway and S-nitrosylation
NF-jB is a heterodimeric transcription factor, usually
comprised of a p50 and p65 subunit, which controls the ex-
pression of many genes involved in innate and adaptive im-
mune responses, including proinflammatory cytokines and
adhesion receptors. The activation of NF-jB itself is controlled
by a tightly regulated protein cascade. In the basal state, the
p50–p65 heterodimer is bound to the inhibitor of NF-jB (IjB),
which maintains the transcription factor inactivated. IjB
phosphorylation by the IKK complex (IKKa, IKKb, and IKKc)
promotes IjB degradation by the 26S proteasome and the
subsequent liberation, translocation into the nucleus, and
DNA binding of NF-jB (50). Distinct stimuli trigger NF-jB
activation (e.g., TNF-a, IFN-c, IL-1b, or LPS) through a series
of pathways that converge on the activation of the IKK com-
plex (66).
NO from exogenous sources or endogenous iNOS ex-
pression can modulate the promoter and DNA-binding ac-
tivity of NF-jB in cells. Indeed, some elements of the
activation pathway of NF-jB, including the subunits of the
transcription factor itself, have been shown to be modified
by S-nitrosylation (Fig. 4).
The p50 subunit of NF-jB is S-nitrosylated at a cysteine
residue located in its DNA-binding domain, which inhibits its
binding to DNA, and thereby decreases the proinflammatory
response (104). Interestingly, S-glutathionylation of the same
cysteine residue also inactivates its DNA binding (137), a
modification likely to be induced by GSNO (86). Likewise,
p65 can also be S-nitrosylated, producing similar conse-
quences, and so nitrosylation of both NF-jB subunits results
in its inactivation (81). IKKb has also been shown to be S-
nitrosylated at Cys179, a modification capable of modulating
kinase function independently of phosphorylation, since
IKKb activity is abrogated after S-nitrosylation after TNF-a
activation (145).
Other elements upstream of NF-jB activation are also
S-nitrosylated. Treatment of the nonreceptor protein tyrosine
kinase p60Src (Src) with nitrosothiol results in Src activation
through autophosphorylation at Tyr416 and the formation
of multimers, an action presumably exerted through S-
nitrosylation at Cys498 and/or the formation of disulfide
bridges between Src monomers (3, 5, 142). Furthermore, in the
TLR-dependent pathway of NF-jB activation, S-nitrosylation
of MyD88 disrupts its binding to the upstream Toll/IL-1R
adaptor protein (TIRAP), but not to the downstream IRAK-1,
which might influence the delayed development of the acute
immune response (70).
CD40 is a member of the TNF receptor (TNFR) family
that when stimulated by CD40L activates the NF-jB pathway
(20). S-nitrosylation of the CD40 extracellular domain occurs in
quiescent macrophages and monocytes, whereas denitrosyla-
tion is produced after activation by CD40L (52). This
FIG. 4. The NF-jB activation
pathway is regulated by S-
nitrosylation. S-nitrosylation
of the p50 and p65 subunits of
NF-jB causes the inhibition of
its binding to DNA. Upstream
inhibition of the IjB-kinase
(IKK) complex’s kinase activity
is induced by S-nitrosylation of
the IKKb subunit, abrogating
NF-jB activation. S-nitrosylation
of CD40 inhibits binding and
activation by CD40L. MyD88
S-nitrosylation disrupts binding
to its upstream partner toll/
interleukin-1 receptor adaptor
protein (TIRAP), which might
serve to delay the development
of the immune response. On
the other hand, S-nitrosylation
of Src may activate NF-jB (To
see this illustration in color, the
reader is referred to the web
version of this article at www
.liebertpub.com/ars).
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modification blocks CD40 signal transduction, such that CD40
denitrosylation could be a prerequisite for macrophage activa-
tion via the CD40 pathway (52). Indeed, CD40 denitrosylation
was observed in mice injected with LPS and in monocytes from
patients suffering severe sepsis or septic shock (52).
It is worth noting that the iNOS gene promoter itself con-
tains NF-jB response elements, and that this transcription
factor is important for iNOS expression (81). Thus, it is feasible
that negative feedback onto S-nitrosylation-dependent NF-jB
inactivation should be taken into account. In this mechanism,
inactivation of IKK/NF-jB by S-nitrosylation could down-
regulate iNOS expression and the associated S-nitrosylation
activity, an effect reinforced by the fact that iNOS itself is
susceptible to inactivation by S-nitrosylation (117, 163). As a
result, NF-jB activation may be equilibrated in cells, and the
levels of NF-jB-induced cytokines and endothelial adhesion
molecules (vascular cell adhesion protein 1, intercellular ad-
hesion molecule 1, and E- and P-selectins) sustained for leu-
kocyte extravasation and function.
As shown by several groups, S-nitrosylation can affect the
NF-jB activation pathway at several points, from the up-
stream molecules to the transcription factor itself. Although
most of the described S-nitrosylation targets (MyD88, CD40,
IKKb, p50, and p65) inhibit the pathway, the modification of
SP-D and Src may activate it. Hence, further studies should
discriminate how these different modifications are integrated
in the regulation of NF-kB.
S-nitrosylation of other relevant proteins and pathways
S100A8 expression is induced by inflammatory mediators
of oxidative stress in macrophages, microvascular endothelial
cells, fibroblast, and keratinocytes. It has chemotactic-, anti-
microbial-, apoptosis-inducing and growth-inhibitory prop-
erties (143). S-nitrosylation of S100A8 at Cys41 could be
important in the resolution of inflammation given that this
modification suppresses mast cell degranulation and mast-
cell-mediated inflammation in the microcirculation (95). In-
teractions between S100A8 and NO produced by endothelial
cells may also alter endothelial cell–leukocyte interactions in
the microcirculation (95).
C-Jun N-terminal kinase ( JNK) belongs to the MAPK
family, and it is the terminal kinase in a pathway composed
byMEKK1 andMKK4/7. Phosphorylation of JNK allows it to
activate target proteins such as c-Jun, a component of the AP-1
transcription factor. This pathway is involved in many dif-
ferent cell activities, including apoptosis, survival, and pro-
liferation. In macrophages activated by IFN-c, when NO is
produced, the activity of JNK is inhibited by a redox mecha-
nism compatible with S-nitrosylation and dependent on
Cys116 (134). This effect is independent of its upstream
partners and of antagonistic stimuli (134), and it may be me-
diated by the disruption of the interaction between JNK and c-
Jun (135). Interestingly, this cysteine residue is only conserved
among the JNK subgroup ofMAPK, which suggests a specific
role for this mechanism that could participate in resolving the
inflammatory response (60). As in the case of the NF-jB
pathway, more complex regulation could occur, as c-Jun
DNA-binding activity is also inhibited by NO-dependent S-
glutathionylation at a critical Cys residue (85), althoughwe do
not know of any study specifically assessing S-nitrosylation of
that residue.
During the inflammatory process, COX-2, a key enzyme in
prostaglandin synthesis, is activated over a similar time
course to iNOS, and crosstalk between these enzymes was
suspected as iNOS-derived NO had been shown to activate
COX (151). In microglia and activated macrophages, iNOS
has been shown to bind and S-nitrosylate COX-2, increasing
its activity (83). Interestingly, COX-2 S-nitrosylation depends
on direct interaction with iNOS, which provides a potential
target for the pharmacological control of this pathway (83),
stressing the role of S-nitrosylation as a short-range signaling
mechanism (106, 110). Indeed, a similar functional interaction
with neuronal NOS has been observed in the context of
NMDA neurotoxicity (175). Additional synergistic regulation
of the COX-2 pathway includes S-nitrosylation of cytosolic
phospholipase A2a (cPLA2a), the rate-limiting enzyme up-
stream of COX, as COX-2 induces the iNOS-dependent
cPLA2a S-nitrosylation that activates this enzyme (192).
Adaptive Immunity: Nitrosothiols in T-Cell-Mediated
Immune Responses
A role for S-nitrosylation in T-cell activation
In the immune system, helper T lymphocytes orchestrate
the responses to pathogenic agents, secreting cytokines whose
function is to coordinate the action of leukocytes and
immune-associated cells. To fulfill the multiple demands on
their effector functions, T lymphocytes proliferate and dif-
ferentiate in response to the action of T-cell receptor (TCR)-
mediated recognition of pathogen-derived antigenic peptides
on antigen-presenting cells (APCs) (162). These cognate in-
teractions result in the phosphorylation-dependent activation
of signaling pathways initiated from the TCR (112). Besides
the importance of protein phosphorylation on key Tyr and
Ser/Thr residues in the activation of signal transduction cas-
cades initiated from the TCR, there is increasing evidence
indicating that protein S-nitrosylation and its redox switch by
denitrosylation are also PTMs able to take part in the regu-
lation of T-cell activation.
T-cell lines and primary T lymphocytes produce NO in
response to TCR engagement with CD3 antibodies, super-
antigens, or antigenic peptides on APCs (69, 165). Despite
some controversies regarding the source of NO and the ex-
pression of NOS isoforms in immune cells of human origin
(155), it has been reported that mouse and human T lym-
phocytes can express iNOS upon viral infection and in re-
sponse to proinflammatory cytokines, or other environmental
factors (25, 87, 119). Nevertheless, the rapid onset of NO
production observed in T cells upon TCR engagement sug-
gests the participation of constitutive rather than inducible
NOS. In this regard, human T lymphocytes express endo-
thelial NOS (eNOS), assessed bymRNA and protein detection
(122, 144, 156), and although mouse T lymphocytes do not
appear to express eNOS mRNA (46), its expression can be in-
duced in murine T lymphocytes upon CD3 stimulation (23).
Hence, species differences or conditioning by factors such as
stimulation, or the origin andheterogeneity of cell samples,may
distort the results of experimental studies.
We reported that eNOS-derived NO is synthesized by T
lymphocytes during antigen-specific interactions with APCs
(69). eNOS is rapidly activated on the Golgi complex by
phosphorylation at Ser1179 due to the combined action of
PI3K/AKT signaling and Ca2 + fluxes. As a consequence, it is
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translocated toward the immune synapse (69), a specialized
intercellular domain where the TCR accumulates along with
signaling and cytoskeletal molecules, and adhesion receptors,
which are organized to regulate the activation of T cells
(34). As a result, early and late TCR-mediated signal trans-
duction events are affected, as eNOS-derived NO increases
the phosphorylation/activation of the TCR CD3f chain and
the adaptor kinase ZAP-70. Moreover, eNOS-derived NO
also activates the MAPK ERK-1 and ERK-2 through the
compartmentalized S-nitrosylation of N-Ras at Cys118 on
the Golgi complex, which facilitates its activation by conver-
sion of GDP- to GTP-bound N-Ras (68) (Fig. 5). Moreover,
using a specific S-nitrosocysteine antibody, we found that
S-nitrosylation is mainly compartmentalized near the Golgi
complex, where active eNOS localizes (68), and a similar
compartmentalization of S-nitrosylation near the foci of NOS
activation has been observed in other cell systems (71). This
localization can be explained by the requirement of high
NO concentrations to produce S-nitrosylation in comparison
with other NO reactions, and it has been postulated as a
mechanism for specific S-nitrosylation of proteins interact-
ing or co-localizing with NOS isoforms, suggesting that
S-nitrosylation is a short-range or proximity-based NO sig-
naling event (30, 106, 110). We showed that although T cells
express both K-Ras and N-Ras (which have the same con-
served Cys residue that can be S-nitrosylated), only N-Ras
FIG. 5. Model of endothelial nitric oxide synthase (eNOS) activation of N-Ras on the Golgi complex of antigen-
stimulated T cells. The figure schematically depicts the possible compartmentalized signaling through which T-cell receptor
(TCR) stimulation may lead to the selective S-nitrosylation and activation of N-Ras on the Golgi complex. Engagement of the
TCR by antigens results in the phosphorylation of the CD3f chain and the recruitment of the adapter kinase ZAP-70. This
kinase in turn phosphorylates LAT and PI3K, leading to activation of PLC-c and Akt, respectively. PLC-c activation produces
diacylglycerol (DAG) in the plasma membrane and inositol 1,4,5-triphosphate (IP3) in the cytosol. IP3 release liberates Ca2 +
from internal stores, which binds to calmodulin-associated eNOS and induces the translocation of RasGRP1 to the Golgi,
where the levels of DAG are high. Simultaneously, active Akt can phosphorylate eNOS on Ser1177. As a result, eNOS might be
fully activated to synthesize NO and S-nitrosylate inactive (GDP-bound) N-Ras on Cys118 (small red arrow). This would
weaken its interaction with GDP, thereby facilitating RasGRP1-mediated GDP-GTP exchange on the Golgi complex (large red
arrow) (To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars).
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is S-nitrosylated due to its localization on the Golgi apparatus
(68), suggesting that specific targets sensitive to regulation
may be S-nitrosylated at the immune synapse.
Our findings also suggest that eNOS-dependent S-
nitrosylation of N-Ras on Cys118 may foster activation-
induced cell death (AICD), a protective mechanism to avoid
the potentially deleterious effects of overactivated T cells (68).
Similarly, other authors have found that treatment with
GSNO stimulates apoptosis in the human promyelomonocy-
tic cell line THP-1, and that mutation of Ras on Cys118 al-
most abrogates apoptosis, further suggesting a role of Ras
S-nitrosylation in cell death (177). Events leading to apoptosis
are activated in the mitochondria through the intrinsic path-
way, or in the case of AICD, they are triggered by death re-
ceptors such as TNFR and CD95/Fas, a member of the TNFR
family that binds to the CD95L/Fas ligand. During AICD,
CD95L interacts with the Fas-associated death domain
(FADD) and recruits procaspase-8, which is proteolytically
activated and released to the cytosol (15).
Although the TNFR may produce antiapoptotic effects
through the activation of NF-jB, binding of soluble TNF-a
and the formation of dead-inducing signaling complexes as-
sociated with the cytoplasmic tail of TNFRmay also represent
a mechanism to sensitize T cells to AICD. In this regard, ni-
trosative stress confers to TNF-a the capacity to promote ap-
optosis in Jurkat T cells by blocking IjBa degradation and the
translocation of NF-jB to the nucleus (105). However, rather
than inducing apoptosis, low-to-moderate concentrations of
NO have been shown to protect T cells from cell death (97).
Caspases are the best-known targets through which NO
exerts its antiapoptotic effects. All caspases contain an es-
sential Cys within their active centers that is sensitive to S-
nitrosylation, and S-nitrosylation of caspase-1, 3, and 9 is
correlated with their enzymatic inhibition in vitro (31, 101).
However, studies carried out in Jurkat T cells suggest that
rather than inhibiting caspase-3 enzymatic activity, NO at-
tenuates its proteolysis to the active form through both the
mitochondrial pathway, by interfering with the Apaf-1/
caspase-9 apoptosome assembly, and the CD95 death recep-
tor pathway, by S-nitrosylation of caspase-1 and 8 (31, 197).
Another S-nitrosylation-dependent mechanism bywhich cells
may be protected from apoptosis involves Bcl-2. In the human
lung epithelial cancer cell line NCI-H460, endogenous NO
produced in response to proapoptotic stimuli inhibits Bcl-2
degradation by S-nitrosylation at Cys158 and 229 (9).
Nevertheless, in some cell systems, neither caspase nor Bcl-2
S-nitrosylation may be sufficient to fully rescue cells from
AICD. In this regard, it has been reported that Ras/MEK/
ERK activation promotes intrinsic apoptosis pathways in
T cells through the phosphorylation and mitochondrial tar-
geting of the orphan nuclear receptor Nur77. Although in
cancer cells Nur77 can bind to Bcl-2 at mitochondria and
convert this antiapoptotic factor into a proapoptotic mediator,
in T cells, Nur77 exerts its actions through an unknown Bcl-2-
independent mechanism (180). Whether eNOS-mediated N-
Ras S-nitrosylation on the Golgi complex of T cells may also
favor apoptosis through an AICD-independent mechanism,
involving ERK-mediated Nur77 phosphorylation/activation,
merits further investigation.
There is increasing evidence of a possible role for deni-
trosylation in T-cell activation. Initial studies on the role of
redox maintenance in T cells indicated that GSH is important
for proliferation and apoptosis, although it only weakly in-
fluences early activation events such as IL-2R expression (114,
153, 164). On the other hand, intracellular GSH levels enable
activation of NF-kB inMolt-4 T cells (115), whereas in Jurkat T
cells, NO inhibits NF-kB activation through S-nitrosylation of
IKKb at Cys179 (145). Hence, reducing environments main-
tained by GSH could be required to counteract the inhibitory
effects exerted by NO-dependent S-nitrosylation on the
proinflammatory transcription factor NF-kB. However, GSH
is not the only reducing or denitrosylating agent involved in
T-cell activation. Trx-maintained reducing microenviron-
ments facilitate the proliferation of T lymphocytes during
antigen-specific interactions with dendritic cells (DCs), and
they buffer apoptosis in primary T lymphocytes and Jurkat T
cells (4, 72). Trxs are expressed in primary T lymphocytes and
T-cell lines, mainly upon mitogenic stimulation in the former
(150, 169, 187), and Trx is particularly prominent in T lym-
phocytes of the intestinal lamina propria. These cells ex-
pressed more Trx than peripheral blood T cells (PBTs), and
they produce more proinflammatory cytokines in response to
activation stimuli (161). Moreover, in experimental studies,
cytokine expression and endogenous Trx in activated PBTs
increase after pretreatment with recombinant Trx. The im-
portance recently attributed to Trx as a cellular enzymatic
system with denitrosylase activity (11, 12, 168) suggests that
its expression in T lymphocytes of the lamina propria may be
important in intestinal microenvironments as a specialized
first line of defense against harmful pathogens, and that this
activity may be regulated by S-nitrosylation.
S-nitrosylation/denitrosylation in T-cell development
During the development of immature T cells into CD4 +
and CD8+ subsets in the thymus, autoreactive CD4 +CD8 +
double-positive thymocytes must be removed by negative
selection, where apoptosis is induced when the TCR strongly
recognizes MHC-presented self-antigens (160). The mecha-
nisms of apoptosis involved in negative selection in the thy-
mus are not well characterized, although it is known that it
differs from that observed in peripheral T lymphocytes, which
mainly proceeds through AICD (133). High levels of NO are
considered important proapoptotic stimuli that can play de-
cisive roles in T-cell selection in the thymus: TCR-stimulated
CD4 +CD8+ thymocytes are highly sensitive to NO-mediated
apoptosis, whereas CD4 +CD8 - and CD4-CD8 + thymocytes
are rather resistant (38). This possibility is supported by
findings showing that increased NO synthesis by iNOS fos-
ters negative selection of CD3-stimulated double-positive
thymocytes (170).
In terms of the mechanisms by which iNOS may regu-
late negative selection, high levels of NO from S-nitroso-N-
acetylpenicillamine have been seen to increase thymocyte
apoptosis via caspase-1 and p53. Moreover, thymocytes from
either caspase-1- or p53-null mice are more resistant to NO-
induced apoptosis, supporting the hypothesis that both
caspase-1 and p53may transmit proapoptotic signals induced
by NO (53, 202). In fact, it has been proposed that NO in-
creases Bax, but reduces Bcl-2 expression through p53 (53).
How the p53/Bax/Bcl-2 axis regulates caspase-1 activation
in thymocytes is a subject of active research. Strikingly, re-
cent studies indicate that S-nitrosylation/denitrosylation is
required for T-cell development. In the thymus of GSNOR-
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deficient mice, there is increased S-nitrosylation (with
GAPDH one of the major proteins identified), apoptosis, and
concomitant reduction of CD4 + thymocytes, a situation that
was normalized in the thymus from iNOS and GSNOR
double knockout mice (195). DCs of the corticomedullary
junction and medulla constitutively express iNOS in the
thymus, and this expression is upregulated after their in-
teraction with thymocytes activated with auto- or alloanti-
gens (2, 170). Hence, NO from thymic stromal DCs may be
an important secondary signal associated to TCR-mediated
apoptosis, and its effects on negative selection may take
place through S-nitrosylation, which can be counteracted by
the denitrosylase activity of GSNOR (Fig. 6). Interestingly,
recent studies carried out in macrophages and neuroblas-
toma cells indicate that iNOS-derived NO S-nitrosylates
GAPDH, and that once S-nitrosylated, GAPDH can trans-
locate to the nucleus after interacting with the E3-ubiquitin
ligase Siah1, where it activates the acetyl transferase activity
of p300/CBP and induces apoptosis by increasing p53 ex-
pression (62, 158). Further work will be required to find
out whether S-nitrosylation/denitrosylation exchange on
GAPDH actually regulates p53-mediated apoptosis during
T-cell development.
By contrast, there is evidence that the selection of CD8 +
and CD4+ T lymphocytes is no different in iNOS-deficient
andwild-type animals (173), suggesting that the denitrosylase
activity of GSNOR during T-cell development may pre-
dominate over the S-nitrosylation activity of iNOS. It remains
unclear how CD4+ maturation is selectively regulated by
GSNOR. One possibility is that thymocytes ongoing CD4+
maturation may be more sensitive to S-nitrosylation-mediated
apoptosis than CD8+ thymocytes. If so,MHC class II-restricted
signals from DCs may upregulate GSNOR expression/
activation in thymocytes undergoing CD4 + maturation, pref-
erentially counteracting the proapoptotic actions of iNOS-
derived S-nitrosylation in those cells. Furthermore, iNOS-in-
dependent S-nitrosylation may also be important for T-cell
development. In this regard, it has been reported that mouse
FIG. 6. Hypothetical S-nitrosylation/denitrosylation mechanisms in T-cell development. (A) Local high extracellular
levels of NO produced by iNOS from corticomedullar and medullar dendritic cells (DCs) in the thymus promote S-
nitrosylation in thymocytes, fostering negative selection of CD4 +CD8+ double-positive thymocytes. Protein S-nitrosylation in
thymocytes may induce apoptosis by increasing p53 expression. The iNOS-derived NO may promote apoptosis through the
S-nitrosylation of GAPDH. S-nitrosylated GAPDH can bind to Siah1 and translocate to the nucleus, where it increases the
acetyltransferase activity of p300/CBP and the ensuing synthesis of p53, which can in turn activate caspase-1 through a still-
to-be determined mechanism. (B) Through denitrosylation, upregulated GSNOR expression or activity in thymocytes on-
going CD4 + maturation may counteract the proapoptotic actions of protein S-nitrosylation mediated by iNOS-derived NO
from DCs. (C) Low levels of NO generated in thymocytes by constitutive NOS (cNOS) during their cognate interactions with
iNOS-nonexpressing DCs and macrophages (antigen-presenting cells [APC]) may protect thymocytes from cell death by S-
nitrosylation of caspase-1 (To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars).
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thymocytes can express constitutive NOS as well as iNOS,
and produce low levels of Ca2 + -induced NO, even in the
presence of iNOS-inducing stimuli such as LPS and proin-
flammatory cytokines (19, 28, 185). It is yet to be seen whether
the antiapoptotic actions of caspase S-nitrosylation generated
by NO from constitutive NOS might also play an important
role in modulating apoptosis during thymocyte maturation.
NO and nitrosothiols in T-cell differentiation
and autoimmunity
Naive CD4 + T lymphocytes recognize antigens in periph-
eral lymphoid organs, provoking the expansion and differ-
entiation of antigen-specific lymphocytes into subsets of
effector cells that can be distinguished on the basis of the
cytokines they produce. Chronic inflammatory diseases are
often dominated by Th1, Th2, and Th17 cells and modulated
by regulatory T cells (Tregs) (94). The most important differ-
entiation-inducing stimuli for Th1, Th2, and Th17 cells are IL-
12, IL-4, and IL-6/IL-23, respectively. The main function of
Th1 and Th17 cells is to activate cellular immunity: Th1 cells
produce IFN-c and TNF-a, whereas Th17 cells produce IL-17
and IL-22. On the other hand, Th2 cells regulate humoral
immune responses typically synthesizing IL-4, IL-5, IL-6, and
IL-10, whereas Tregs mainly produce IL-10 and have been
implicated in the generation of tolerance to exacerbated in-
flammatory responses (94).
The regulation of cytokines by NO has received consider-
able attention, because it might be relevant in the selection of
adaptive immune responses and the management of auto-
immune chronic inflammation (Table 1). The first solid evi-
dence of a role for NO in T-cell differentiation came from a
seminal study carried out in iNOS-deficient Balb/c mice,
which generated Th1 responses upon Leishmania major infec-
tion instead of the characteristic Th2 polarization associated
with control Balb/c mice (182). Later studies demonstrated
that high NO concentrations promoted Th2 differentiation by
suppressing IL-12 synthesis in activated macrophages (67).
Since then, iNOS has been associated with the incidence and
severity of many chronic inflammatory diseases, such as
rheumatoid arthritis (113, 121), systemic lupus erythematosus
(123), experimental autoimmune uveitis (EAU) (172), experi-
mental autoimmune encephalomyelitis (EAE) (184), and
asthma (58).
Th1 Differentiation. Several reports support the hypoth-
esis that nitrosothiols may be behind the actions of NO in Th1
differentiation. In a murine model of autoimmune hepatitis
induced by concanavalin-A activation of Fas-regulated apo-
ptosis (148, 176), high levels of NO from NO-aspirin (NCX-
4016) or from a NO derivative of ursodeoxycholic acid (NCX-
1000) reduced Th1 responses by inhibiting the caspases in-
volved in the processing and production of Th1 cytokines (39,
40). This effect was reverted when cell lysates were treated
with DTT or HgCl2, which are able to reduce oxidized cys-
teines (including S-nitrosothiols), suggesting that the inhibi-
tory effect of NO on caspase activity could be achieved via the
S-nitrosylation of essential cysteine residues within their cat-
alytic site (39).
Moreover, Trx induction in T lymphocytes increased
production of Th1 cytokines by stimulating IFN-g gene ex-
pression (79). Therefore, it seems likely that high levels of
NO generated by iNOS may prevent overexpansion of Th1
cells by S-nitrosylation of key transcriptional and post-
transcriptional regulators of Th1 pathways. By contrast,
low concentrations of NO stimulate T cells to express IL12-
Rb2 and promote Th1 differentiation via cGMP (130).
Nevertheless, since Th1 cells are more sensitive to apoptosis
induced by high concentrations of NO than Th2 cells (149),
and low-to-moderate concentrations of NO can exert S-
nitrosylation-mediated antiapoptotic effects, the influence of
NO from constitutive NOS may improve Th1 viability and
influence the Th1/Th2 balance. Indeed, it has been reported
that Ras/MAPK signaling also plays an important role in T-
cell differentiation: strong signals from the antigen-engaged
TCR sustain ERK activation and favor Th1 differentiation,
whereas weak and transient TCR-mediated activation of
ERKs preferentially induces Th2 differentiation, a conse-
quence of increased Jak-1, STAT-6, and GATA-3 activation
(193). A possible role for NO in Ras/ERK-mediated Th1/Th2
differentiation is supported by eNOS and NO donors regu-
lating ERK activity through Ras S-nitrosylation (68, 91).
Nevertheless, a recent study analyzing eNOS-deficient
C57BL/6 mice infected with L. major clearly showed that
eNOS does not play any role in the selection of the Th1/Th2
immune response to infection, although it enhanced granu-
locyte infiltration into lesions (46). However, it remains
possible that the actions of eNOS-derived NO in human and
mouse T-cell differentiation could be species specific (see
above).
Uveitis represents a group of sight-threatening intraocular
inflammatory diseases, including Behc¸et’s disease, birdshot
retinochoroidopathy, sympathetic ophthalmia, Vogt-Koyanagi-
Harada’s disease, and ocular sarcoidosis, which may have an
autoimmune etiology (131). EAU can be induced in suscep-
tible rodent species by immunization with the retinal protein,
interphotoreceptor retinoid-binding protein (IRBP) (181).
GSNO treatment ameliorates the disease due to its ability to
inhibit retinal expression of Th1 cytokines and T-cell prolif-
eration (61). In an earlier report, administration of IL-12 to
these animals protected them from disease due to apoptotic
deletion of detrimental T cells, inducing IFN-c overproduc-
tion and iNOS-derived NO (172). While not specifically as-
sessed, these results suggest that Th1 cells could be the subset
of detrimental T cells depleted. More recent work indicates
that uveitis is also associated with Th17 response (24, 181),
although we have not found reports of nitrosothiols partici-
pation in Th17-dependent uveitis.
Th17 Differentiation. Multiple sclerosis (MS) is a common
inflammatory disease of the central nervous system (CNS)
characterized by the instability and disruption of myelin, the
death of oligodendrocytes and axonal damage (80). A murine
EAE model of MS involves the induction of a neuroin-
flammatory disease by immunization with antigens derived
from myelin protein. This animal model is associated with
impaired integrity of the blood–brain barrier, upregulation of
adhesion molecules, and the invasion of vascular inflamma-
tory cells into the CNS.
In the recent years, increasing importance has been given to
Th17 cells as mediators of EAE, and NO has emerged as a
possible regulator of Th17 proliferation and function. NO
inhibits the proliferation and function of polarized Th17 cells,
and EAE is more severe in iNOS-deficient mice than in wild-
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type controls (128). Moreover, GSNO attenuates EAE, pro-
tecting myelin by restricting mononuclear cell infiltration and
inhibiting proinflammatory mediator expression (TNF-b,
IFN-c, and IL-1b), as well as by reducing IL-17 production
through the inactivation of STAT-3 and the reduction of RORc
expression, two essential transcription factors for Th17 cell
differentiation and function (139).
In EAE mice, differences in the S-nitrosoproteome have
been described by comparative biotin-switch and western
blot analysis, affecting cytoskeletal components (neurofila-
ment proteins, tubulin, and b-actin), metabolic enzymes
(GAPDH and neuronal-specific enolase), ion-channel-related
proteins (glutamate receptor NR2A), and myelin proteins
(2¢,3¢-cyclic nucleotide 3¢-phosphodiesterase) (14). Such find-
ings argue in favor of a neuroprotective role of iNOS-derived
NO in EAE, possibly through S-nitrosylation of specific
targets in Th17 cells. Nevertheless, since most of the S-
nitrosylated proteins identified in the aforementioned study
are abundant cellular proteins, in-depth screening with more
sensitive proteomic approaches would be required in EAE-
infiltrated T cells to search for key S-nitrosylation targets that
may influence Th17 differentiation and function. Conversely,
the participation of NO in the etiopathology of EAE is not
an exclusive hallmark of iNOS. In EAE studies with eNOS-
deficient mice, eNOS-derived NO appears to favor the re-
cruitment of T lymphocytes to the CNS, whereas it attenuates
EAE exacerbation. Thus, eNOS fulfills proinflammatory and
neuroprotective roles during the course of the disease (191).
Whether this latter effect involves protein S-nitrosylation re-
mains to be investigated.
Th2 and Tregs. The preferential role for oxidative stress
and superoxide in the differentiation toward Th2 phenotypes
has recently been highlighted (23, 84). There is also evidence
indicating that nitrosothiols may be important for Th2 dif-
ferentiation and function. Treatment of human bronchial ep-
ithelial cells with NO reversibly suppresses proliferation of
activated Th2 cells in atopic asthma (35). Moreover, S-ni-
trosylated proteins are substantially reduced in asthmatic
patients, correlating fairly well with the increased GSNOR
levels in their bronchoalveolar fluids (140). These findings are
supported by studies carried out in an experimental mouse
model of asthma, in which mice deficient in the expression of
GSNOR were protected against hypersensitivity to the spe-
cific allergen and against hyper-reactivity to bronchocon-
strictors by increasing the levels of iNOS-derived S-
nitrosylated proteins in the lungs, an effect reverted by
treatment with NOS inhibitors (141). Furthermore, proteomic
studies of T lymphocytes have shown that Trx and other re-
dox control proteins are increased in T cells from asthmatic
patients with respect to healthy controls (77).
Several types of Tregs have been implicated in the gener-
ation of tolerance to exacerbated inflammatory responses.
These include natural and adaptive CD4+ CD25+ , Foxp3 +
Tregs. Natural Tregs develop in the thymus, whereas adap-
tive Tregs can be generated by repetitive antigen presentation
to naive CD4 +CD25- T cells by immature or tolerogenic DCs
(22, 78, 179). Although recent studies have clearly shown that
NO can negatively regulate classical Treg differentiation by
inhibiting Foxp3 expression, supposedly through a cGMP-
dependent mechanism (16, 93), several lines of evidence do
not exclude a role for iNOS-derived NO and S-nitrosylation in
the function of Tregs. First, in response to autoantigens, Tregs
secrete IFN-c and induce iNOS-derived NO production by
APCs. The APC-derived NO suppresses the proliferation of
pathogenic T cells, thereby inhibiting the course of autoim-
mune diseases (8, 21, 171). Second, DCs expressing a kinase-
defective dominant-negative form of Ikappa B kinase-2
(dnIKK2) show an impaired allostimulatory ability to upre-
gulate MHC-II antigens and costimulatory molecules in re-
sponse to either LPS or CD40 engagement (2). Naivemurine T
cells stimulated with antigen-loaded immature dnIKK2 DCs
differentiate into CD4 +CD25 - Tregs (dnIKK2-Tregs). These
Tregs express iNOS, and have the ability to inhibit naive and
preactivated T-cell responses in vitro (1). Finally, recent
studies demonstrated the existence of a population of Tregs
(NO-Treg) generated by NO in a cGMP-independent man-
ner via p53-mediated expression of antiapoptotic genes and
local secretion of IL-2 (129). NO-Tregs are a subset of T lym-
phocytes induced by NO together with TcR-mediated acti-
vation. They are CD4+CD25 + , Foxp3- , GITR + , and CD27 + ,
and they have a Th2 phenotype that suppresses CD4 +CD25 -
effector T cells, exerting their activities in an IL-10-dependent
manner. Nonetheless, there is still no consistent evidence
that NO-involved Treg functions may take place through
S-nitrosylation, beyond a recent report indicating that
Tregs express high levels of Trx-1, which may confer resis-
tance to the characteristic oxidative stress of inflammatory
foci (120).
Collectively, these diverse lines of evidence suggest that
NO can regulate T-cell differentiation and function through a
variety of mechanisms, some of them involving the partici-
pation of S-nitrosylation, which provides benefits in the
course of chronic inflammatory diseases, presumably by
disturbing the differentiation and/or function of Th1, Th2,
and/or Th17 cells, while the effects on Tregs remain un-
known.
S-Nitrosylation as a Therapeutic Agent in Chronic
Inflammatory Diseases
Crohn’s disease is a chronic inflammatory disease of the
gastrointestinal tract, which is probably caused by an imbal-
ance between proinflammatory and anti-inflammatory me-
diators, and is associated with a permeability disorder of the
mucosal barrier (26, 138) (Table 1). A murine model of the
disease has been obtained by expressing the herpes simplex
virus thymidine kinase (HSV-Tk) gene under the control of the
astroglial-specific promoter for glial fibrillary acid protein
(GFAP). Ganciclovir administration provokes enteric glial
ablation in this model, leading to intestinal inflammation and
an apparent disruption of the intestinal epithelial monolayer
(18). In these mice, GSNO was implicated in promoting the
function of the mucosal barrier (154). At low concentrations,
and unlike GSH or GSSG, GSNO reduced the intestinal per-
meability caused by enteric glial cell ablation, and it protected
these transgenic mice from intestinal inflammation. ZO-1 is a
protein implicated in the formation of tight junctions, and its
interaction with actin might directly regulate barrier integrity
and permeability. ZO-1 expression increased after exposure to
GSNO exposure, a possible means by which GSNO might
help maintain mucosal barrier function. This protein may also
be regulated by GSNO through PTMs, since ZO-1 protein has
a cysteine in a transnitrosylation consensus motif situated in
300 HERNANSANZ-AGUSTI´N ET AL.
the C-terminal actin-binding region (154). Future studies
might elucidate the mechanisms involved.
Mannose-binding lectin (MBL) is a complement-activating
protein involved in innate immune defense. MBL deficit or
dysfunction is associated with autoimmune diseases such
as lupus erythematosus and rheumatoid arthritis (55, 82). S-
nitrosylated MBL was detected in synovial fluid of rheuma-
toid arthritis patients (59, 65), and there is evidence of the
potential harmful effects that S-nitrosylation of MBL might
provoke in such patients, including impaired function (man-
nan binding, complement deposition, bacterial opsonization,
agglutination and phagocytosis, and induction of apoptosis)
and increased anti-MBL autoantibody generation (59). Given
the possible conformational changes in the MBL structure
after S-nitrosylation of one or some of its cysteines, it would be
of interest to further investigate these potential changes and
which cysteine residues might be modified.
Inhaled NO has been used therapeutically in the treat-
ment of acute lung injury, a poorly understood inflamma-
tory syndrome with a significant influence on public health
(33). Nevertheless, NO might be not so efficient in treating
this disease, since its use may increase the formation of
deleterious RNS. By studying lung inflammation in a
mouse model of LPS-induced airway injury, it was recently
shown that inhalation of ethyl nitrite (ENO), a gas that
fosters S-nitrosylation, may decrease lung inflammation
and injury in mice by inhibiting epithelial activation in the
airways (103). S-nitrosylation homeostasis in the lung was
disrupted on LPS treatment, which reduced S-nitrosylation
levels and increased NF-jB activation, which was pre-
vented by pretreatment with the S-nitrosylating agent ENO
(103).
In conjunction, the findings that managing the levels of
S-nitrosylation may be useful in treating those chronic in-
flammatory diseases in which S-nitrosylation homeostasis
is altered considerably are promising. In this regard, S-
nitrosylating/denitrosylating agents may represent thera-
peutic tools for the prevention and/or treatment of this group
of diseases. Thus, it is reasonable to expect that in the coming
years, these tools could be further developed into more effi-
cient treatments.
Conclusions
S-nitrosylation is increasingly being considered as a
signaling mechanism in many cells and systems. In the
immune system, several signaling pathways are modulated
by this oxidative PTM in the regulation of T-helper cell re-
sponses during adaptive immunity, as well as in the innate
immunity mediated by phagocytes. Indeed, self-protection
mechanisms of macrophages, specialized cells that use NO
and RNS production as antimicrobial weapons, have begun
to be uncovered. Further work will be required to study
these issues in more detail within broader contexts, both
from the molecular and pathophysiological points of view,
which will benefit from methodological improvements to
analyze and quantify the S-nitrosoproteome. There is ac-
cumulating evidence of the positive role for nitrosothiols
and S-nitrosylation in T-cell regulation, demonstrating
beneficial effects in autoimmune disease models, which
certainly could be further explored and potentially trans-
lated to improve disease treatment.
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Abbreviations Used
2-DE¼ two-dimensional electrophoresis
AICD¼ activation-induced cell death
APCs¼ antigen-presenting cells
BST¼ biotin-switch technique
CNS¼ central nervous system
COX-2¼ cyclooxygenase-2
cPLA2a¼ cytosolic phospholipase A2a
CRD¼ carbohydrate-recognition domain
DAG¼diacylglycerol
DCs¼dendritic cells
dnIKK2¼dominant-negative form of Ikappa B
kinase-2
EAE¼ experimental autoimmune
encephalomyelitis
EAU¼ experimental autoimmune uveitis
ENO¼ ethyl nitrite
eNOS¼ endothelial NOS
GFAP¼ glial fibrillary acid protein
GSH¼ glutathione
GSNO¼ S-nitrosoglutathione
GSNOR¼ S-nitrosoglutathione reductase
HDAC2¼histone deacetylase 2
HSV-Tk¼herpes simplex virus thymidine kinase
IFN-c¼ interferon-c
IKK¼ IjB-kinase
IL-1R¼ interleukin-1 receptor
iNOS¼ inducible nitric oxide synthase
IP3¼ inositol 1,4,5-triphosphate
IRAK¼ IL-1R-associated kinase
IRBP¼ interphotoreceptor retinoid-binding
protein
JNK¼C-Jun N-terminal kinase
LPS¼ lipopolysaccharide
MAPK¼mitogen-activated protein kinase
MBL¼mannose-binding lectin
MS¼multiple sclerosis
NO¼nitric oxide
PBTs¼peripheral blood T cells
PTM¼post-translational modification
RNS¼ reactive nitrogen species
SIRP-a¼ signal inhibitory regulatory protein a
SNAP¼ S-nitroso-N-acetylpenicillamine
SP-D¼ surfactant protein D
TCR¼T-cell receptor
TIRAP¼Toll/interleukin-1 receptor adaptor
protein
TLR¼ toll-like receptor
TNF¼ tumor necrosis factor
TNFR¼ tumor necrosis factor receptor
Tregs¼ regulatory T cells
Trx¼ thioredoxin
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